|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0017262,
umls-concept:C0038952,
umls-concept:C0045093,
umls-concept:C0185117,
umls-concept:C0205251,
umls-concept:C0439590,
umls-concept:C1333355,
umls-concept:C2911684
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-7-12
|
|
pubmed:abstractText |
Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Recent evidence indicates that Gemcitabine (Gem) may modulate ERCC1 nucleotide excision repair activity, and down-regulation of DNA repair activity by ERCC1 antisense RNA reportedly inhibits synergism of CDDP/Gem. We investigated whether ERCC1 mRNA expression levels were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AlberolaVicenteV,
pubmed-author:BrabenderJanJ,
pubmed-author:CampsCarlosC,
pubmed-author:CardenalFelipF,
pubmed-author:DanenbergKathleen DKD,
pubmed-author:DanenbergPeter VPV,
pubmed-author:DomineManuelM,
pubmed-author:GandaraDavidD,
pubmed-author:GumerlockPaul HPH,
pubmed-author:LordReginald V NRV,
pubmed-author:RosellRafaelR,
pubmed-author:SánchezJosé JJJ,
pubmed-author:SánchezJosé MJM,
pubmed-author:TarónMiquelM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2286-91
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12114432-Adult,
pubmed-meshheading:12114432-Aged,
pubmed-meshheading:12114432-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12114432-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12114432-Cisplatin,
pubmed-meshheading:12114432-DNA-Binding Proteins,
pubmed-meshheading:12114432-Deoxycytidine,
pubmed-meshheading:12114432-Endonucleases,
pubmed-meshheading:12114432-Female,
pubmed-meshheading:12114432-Follow-Up Studies,
pubmed-meshheading:12114432-Humans,
pubmed-meshheading:12114432-Lung Neoplasms,
pubmed-meshheading:12114432-Male,
pubmed-meshheading:12114432-Middle Aged,
pubmed-meshheading:12114432-Prospective Studies,
pubmed-meshheading:12114432-Proteins,
pubmed-meshheading:12114432-RNA, Messenger,
pubmed-meshheading:12114432-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12114432-Survival Rate,
pubmed-meshheading:12114432-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
|
|
pubmed:affiliation |
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
